RNS Number : 2475O
MaxCyte, Inc.
25 June 2025
 

A black letter on a white background AI-generated content may be incorrect.

 

 

MaxCyte Inc.

("MaxCyte" or the "Company")

Last Day of Dealings on AIM

 

ROCKVILLE, Md., LONDON, UK., 25 June, 2025 MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics today provides a further update with regards to the cancellation of admission of the Company's common stock ("Common Stock") to trading on AIM (the "Cancellation"), as approved by shareholders at the Annual General Meeting held on 18 June 2025.

Shareholders are reminded that the last day of dealings in the Company's Common Stock on AIM will be 25 June 2025 and that the cancellation of their admission to trading on AIM will take place at 7:00 a.m. (UK time) on 26 June 2025.

Following the delisting, there will be no public market in the United Kingdom on which the Common Stock can be traded, however the Company will retain its U.S. listing of Common Stock on the Nasdaq Global Select Market ("Nasdaq") under ticker symbol MXCT.

Further information regarding the delisting can be found at: https://investors.maxcyte.com/static-files/529f4a8b-c6e9-4db6-bfc1-6a2da9f0252a.

For further information, please contact:

 


MaxCyte Contacts:

US IR Adviser

Gilmartin Group

David Deuchler, CFA

 

 

+1 415-937-5400

ir@maxcyte.com

 



Nominated Adviser and Joint Corporate Broker

Panmure Liberum

Emma Earl / Mark Rogers

Corporate Broking

Rupert Dearden

 

+44 (0)20 7886 2500



 

UK IR Adviser

ICR Healthcare

Mary-Jane Elliott

Chris Welsh 

 

+44 (0)203 709 5700

maxcyte@icrhealthcare.com

 


 

About MaxCyte

At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure DX™ gene editing risk assessment services enable precise, efficient and scalable cell engineering. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine. Learn more at maxcyte.com and follow us on X and LinkedIn.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFIMFTMTBTBLA